Development of a synthetic cannabinoid program

合成大麻素计划的开发

• 批准号: 530888-2018
• 负责人: Mcnulty, James
• 金额: $ 5.83万
• 依托单位: McMaster University
• 依托单位国家: 加拿大
• 项目类别: Collaborative Research and Development Grants
• 财政年份: 2019
• 资助国家: 加拿大
• 起止时间: 2019-01-01 至 2020-12-31
• 项目状态: 已结题
• 来源: https://www.nserc-crsng.gc.ca/ase-oro/Details-Detailles_eng.asp?id=692128
• 关键词: Development; synthetic; cannabinoid; program

This research proposal is concerned with the development of a totally synthetic chemical platform to access cannabidiol (CBD). CBD is a minor constituent in cannabis (Cannabis sativa) resin and is non-psychoactive and non-addictive. CBD has a growing list of therapeutic applications, for example in pain management such as migraine and neuropathic pain, as well as treatment of epilepsy and seizures. While natural cannabis resin is expected to be descheduled on October 17th 2018, access to synthetic CBD alleviates many of the problems (cost, inconsistent levels, fungal and insect infestations etc) faced in the growing cannabis industry. Reliable synthetic access to CBD will allow for reliable production and preparation of analogs that will permit a thorough investigation into the pain-management indications of this non-opiate based analgesic.

这项研究计划涉及开发一个完全合成的化学平台来获取大麻二酚（CBD）。 CBD是大麻（Cannabis sativa）树脂中的一种次要成分，不具有精神活性和非成瘾性。CBD具有越来越多的治疗应用，例如在疼痛管理中，如偏头痛和神经性疼痛，以及癫痫和癫痫发作的治疗。虽然天然大麻树脂预计将于2018年10月17日被取消，但合成CBD的使用会导致大麻行业面临的许多问题（成本，不一致的水平，真菌和昆虫感染等）。可靠的CBD合成途径将允许可靠的生产和制备类似物，这将允许对这种非阿片类镇痛剂的疼痛管理适应症进行彻底调查。